Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
Daclizumab discontinue letter for the US market
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis.
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
EMD Serono
Pregnancy outcomes in patients exposed to interferon beta-1b.
Glatiramer acetate in the treatment of multiple sclerosis
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy.
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II).
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
BTG plc Close Period Update

Pages